David Bogoslaw
Life sciences investor Catalio Capital Management has been on a fundraising tear since it spun out of private equity firm Camden Partners Holdings slightly more than two years ago. If dealmaking continues to founder in a sputtering economy, Catalio will be well positioned to take advantage of declining valuations.
The Column Group is close to reaching its fundraising target of $600m apiece for its early-stage life science Fund V and later-stage Opportunity Fund III.
The fact three firms led by women raised multi-billion funds within a couple of months is worth celebrating, but female-led venture capital funds still account for a fraction of the industry.